ASTRO Releases New Prostate Cancer Radiation Guidelines

The updated standards favor shorter treatment durations for localized prostate cancer patients across all risk groups.

Updated on Oct. 28, 2026 in Cancer

Isometric editorial illustration of a geometric radiotherapy gantry in a clean, clinical environment, representing updated oncology standards. — The American Society for Radiation Oncology released new guidelines recommending shorter-course radiation therapy for localized prostate cancer patients in the U.S. AI Illustration. Upload story photo >

Live Poll

Do you trust that shorter-course radiation therapy guidelines will improve prostate cancer care?

The American Society for Radiation Oncology has issued new clinical guidelines recommending shorter-course external beam radiation therapy. The updated standards replace previous recommendations from 2018.

Why it matters

The shift toward shorter treatment schedules is supported by clinical evidence, offering patients more efficient options for managing localized prostate cancer. The guidelines aim to standardize the use of moderate and ultrahypofractionation across all risk groups.

Randomized trials involving more than 7,000 patients support the use of moderate hypofractionation. Dosing ranges from 6,000 cGy to 7,000 cGy for moderate treatment and 3,625 cGy to 4,000 cGy for ultrahypofractionation.

The players

American Society for Radiation Oncology

This professional organization develops standards and guidelines for the practice of radiation oncology in the United States.

The details

The new guidance strongly supports five-session stereotactic body radiation therapy as a standard option for patients. It advises against using regimens of fewer than five fractions outside of a clinical trial setting.

2018: Previous ASTRO recommendations were published.
October 27, 2026: Updated guideline was published in Practical Radiation Oncology.

Health Landscape

The publication of these new standards updates and replaces the framework previously established by the American Society for Radiation Oncology clinical guidelines in 2018. This shift reflects a broader medical move toward more efficient, shorter-duration radiation protocols.

Patients may now discuss shorter treatment timelines, such as moderate or ultrahypofractionation, with their oncologists as standard options. These regimens reduce the time spent in treatment sessions compared to conventional fractionation methods.

The takeaway

These updated guidelines suggest a significant shift toward shorter, more convenient radiation therapy schedules for many prostate cancer patients. Patients should consult with their healthcare providers to determine which specific radiation protocol aligns with their clinical risk profile.